Apogen Biotechnologies, a US-based oncological therapy spinout of University of Minnesota, boosted its series A round to $11m yesterday with a $4m extension from investors including pharmaceutical firm Merck Group. Merck contributed to the capital through its corporate venturing subsidiary M Ventures, and was joined by unnamed, existing investors. Apogen previously raised an initial $7m…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.